Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 12/2005

01-12-2005 | Editorial

Supportive care in oncology

Author: Robert E. Coleman

Published in: Supportive Care in Cancer | Issue 12/2005

Login to get access

Excerpt

Bisphosphonates are an important component of the multidisciplinary management of metastatic breast cancer and have made a significant contribution to improving the quality of life and functional independence of the many patients who, despite the developments in adjuvant therapy, still develop advanced disease [1]. Following some 20 years of randomised trials, we now have a range of agents available in Europe and a choice of oral and intravenous formulations. Unfortunately, very few of the studies to date have directly compared two bisphosphonates in trials with sufficient power to identify likely differences. As a result indirect comparisons of efficacy, toxicity, convenience and health economics are frequently made. However, the conclusions of such comparisons more often reflect the opinion (bias) of the author(s) than the science within the individual studies. …
Literature
1.
Brown J, Neville-Webbe H, Coleman RE (2004) The role of bisphosphonates in breast and prostate cancers. Endocr Relat Cancer 11:207–224CrossRefPubMed
2.
Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE (2003) Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer 89(11):2031–2037
3.
Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee K-A, Zheng M, Hei Y-J (2005) Coleman RE Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97(1):59–69
4.
Vinholes J, Coleman R, Lacombe D, Rose C, Tubiana-Hulin M, Bastit P, Wildiers J, Michel J, Leonard R, Nortier J, Mignoloet F, Ford J (1999) Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen crosslink excretion. Br J Cancer 80(1/2):221–228
5.
Gnant M, Jakesz R, Mlineritsch B et al (2004) Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole vs goserelin plus tamoxifen-bone density sub-protocol results of a randomised multicentre trial (ABCSG-12). Breast Cancer Res Treat 88(Suppl1):S8 Abstract 6
6.
Lester J, Dodwell D, McCloskey E, Coleman R (2005) The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 31:115–142CrossRefPubMed
Metadata
Title
Supportive care in oncology
Author
Robert E. Coleman
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 12/2005
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0860-1

Other articles of this Issue 12/2005

Supportive Care in Cancer 12/2005 Go to the issue

Original Article

Motives for becoming and remaining member of patient associations: a study of 1,810 Swedish individuals with cancer associations

Original Article

The relationship between fatigue and light exposure during chemotherapy

Original Article

Ending treatment: the course of emotional adjustment and quality of life among breast cancer survivors immediately following radiation therapy

Forthcoming Meetings

Forthcoming Meetings December 2005

Supportive Care International

Spirituality, psychotherapy and music in palliative cancer care: research projects in psycho-oncology at an oncology center in Switzerland

Original Article

Experience in the use of the palliative care outcome scale
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits